O

Oruka Therapeutics

Clinical-stage antibody therapies for psoriasis

Senior Medical Director, Pharmacovigilance and Safety

Biology & BiotechConfirmed live in the last 24 hours
Full-time

About the Job

Requirements

  • A medical degree (MD/DO or equivalent) and completed residency are required.
  • At least 6 years of safety experience within the pharmaceutical industry is required.
  • Expertise in global pharmacovigilance regulations and requirements is required.
  • Proficiency with safety surveillance systems and tools such as Argus, MedDRA, and Veeva Vault is required.
  • The candidate must be able to work effectively in a dynamic, cross-functional, and fast-paced team environment.
  • Strong communication, leadership, and analytical skills are required.

Responsibilities

  • Develop and lead product safety surveillance strategies, identify emerging clinical safety issues, and recommend appropriate risk-mitigation measures.
  • Conduct or oversee routine and ad hoc safety-data reviews, monitor for safety signals, and maintain awareness of relevant drug-class and competitor safety issues.
  • Lead ongoing aggregate safety review and chair internal safety governance committees.
  • Plan and interpret safety-data analyses, and prepare and present safety-data summaries to internal and external stakeholders.
  • Build working relationships with clinical study teams, safety vendors, and business partners to align on product safety strategy.
  • Oversee expedited safety reporting, including medical review of Individual Case Safety Reports, suspected unexpected serious adverse reactions, and other reportable safety events.
  • Ensure appropriate medical follow-up and consistent medical assessment of individual safety cases.
  • Provide medical review of clinical-trial safety data, including adverse events, laboratory results, vital signs, ECGs, exposure data, and relevant nonclinical or external information.
  • Provide medical safety guidance to investigators, study teams, and internal stakeholders.
  • Lead safety-related aggregate reporting and prepare and maintain relevant sections of Investigator's Brochures, including Reference Safety Information, Development Safety Update Reports, Risk Management Plans, and other regulatory documents.
  • Provide safety input into clinical development plans, study protocols, informed consent forms, case report forms, statistical analysis plans, data-monitoring plans, and clinical study reports.
  • Represent Pharmacovigilance in correspondence and meetings with the FDA and other global regulatory authorities.
  • Maintain current knowledge of global pharmacovigilance regulations and guidance and ensure activities comply with applicable requirements, standard operating procedures, and internal guidelines.
  • Help build and continuously improve the pharmacovigilance system as the company and clinical portfolio grow.
  • Oversee pharmacovigilance vendors supporting case processing, safety-database management, aggregate reporting, and literature surveillance.
  • Set clear vendor expectations, monitor quality and performance, and ensure timely resolution of issues.
  • Provide safety leadership for independent data monitoring committees and adjudication committees, including developing charters, data-review plans, meeting materials, and recommendations.
  • Support inspection readiness and represent Pharmacovigilance during regulatory inspections, audits, and due-diligence activities.

About the Company

Oruka Therapeutics

Clinical-stage antibody therapies for psoriasis

Oruka Therapeutics develops antibody-based therapies for chronic skin diseases, focusing on plaque psoriasis and psoriatic arthritis. Its monoclonal antibodies, discovered and engineered by Paragon Therapeutics, are designed for longer dosing intervals to improve patient convenience. ORKA-001 targets IL-23p19 with an extended half-life that could allow dosing once or twice a year, while ORKA-002 targets IL-17A/F with dosing two to three times per year; both are in early-stage trials with Phase 2 planned for 2025–2026. The company aims to deliver higher skin clearance and durable remission to the large patient pool, pursuing commercialization after advancing through clinical trials; it entered public markets via a 2024 reverse merger with ARCA biopharma and raised over $475 million to fund operations through 2027.

Company size
11-50
Company stage
IPO
Headquarters
Waltham, MA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Oruka Therapeutics

See more jobs